181 related articles for article (PubMed ID: 8952859)
1. Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.
Sagripanti A; Ferretti A; Nicolini A; Carpi A
Biomed Pharmacother; 1996; 50(8):376-82. PubMed ID: 8952859
[TBL] [Abstract][Full Text] [Related]
2. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
3. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study.
Pogliani E; Milani M
J Int Med Res; 1996; 24(3):311-5. PubMed ID: 8725994
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
[TBL] [Abstract][Full Text] [Related]
6. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Michiels JJ; van Genderen PJ; Lindemans J; van Vliet HH
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():47-56. PubMed ID: 8951772
[TBL] [Abstract][Full Text] [Related]
7. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
10. Aspirin in essential thrombocythemia: status quo and quo vadis.
Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
[TBL] [Abstract][Full Text] [Related]
11. Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Xie J; Geng L; Yuan B; Guo Y; Zhang Z
BMC Neurol; 2020 Nov; 20(1):407. PubMed ID: 33158429
[TBL] [Abstract][Full Text] [Related]
12. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Michiels JJ
Pathol Biol (Paris); 2003 Apr; 51(3):167-75. PubMed ID: 12781799
[TBL] [Abstract][Full Text] [Related]
13. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Jan; 5(1):30-6. PubMed ID: 10725980
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
17. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
Michiels JJ; van Genderen PJ; Jansen PH; Koudstaal PJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():65-70. PubMed ID: 8951774
[TBL] [Abstract][Full Text] [Related]
18. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients.
Cocozza M; Picano T; Oliviero U; Russo N; Coto V; Milani M
Stroke; 1995 Apr; 26(4):597-601. PubMed ID: 7709404
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Cortelazzo S; Finazzi G; Ruggeri M; Vestri O; Galli M; Rodeghiero F; Barbui T
N Engl J Med; 1995 Apr; 332(17):1132-6. PubMed ID: 7700286
[TBL] [Abstract][Full Text] [Related]
20. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Gadisseur A; Lam KH; De Raeve H; Schroyens W
Acta Haematol; 2015; 133(1):56-63. PubMed ID: 25116182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
